Sign In
Buy CVAC
$5.28
+0 (+0%)
At Close: Nov 17, 2025
CureVac: The Hidden Value Of The mRNA Wallet
05:26am, Wednesday, 01'st Oct 2025
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
07:50am, Friday, 15'th Aug 2025
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acqui
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
02:51am, Friday, 08'th Aug 2025
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine te
CureVac settles patent dispute litigation with Pfizer and BioNTech
09:00pm, Thursday, 07'th Aug 2025
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
CureVac Announces Voting Results of General Meeting
04:35pm, Tuesday, 24'th Jun 2025
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
12:56pm, Friday, 20'th Jun 2025
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
09:24am, Friday, 20'th Jun 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
01:19pm, Friday, 13'th Jun 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
12:05pm, Thursday, 12'th Jun 2025
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow
CureVac Stock Soars on BioNTech Buyout
11:08am, Thursday, 12'th Jun 2025
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
11:07am, Thursday, 12'th Jun 2025
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
10:34am, Thursday, 12'th Jun 2025
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms,
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
08:39am, Thursday, 12'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
07:11am, Thursday, 12'th Jun 2025
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
07:03am, Thursday, 12'th Jun 2025
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
